Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Q1 2025 earnings

Reported April 8, 2025 · Before market open

Revenue$18.5MBeat by $2.6M
EPS-$0.67Beat by $0.05
Revenue estimate$15.8M
EPS estimate-$0.72

Next report

Oct 8, 2026 (In 2 weeks)
Revenue estimate$24.3M
EPS estimate-$0.60

Financials

Q1 2025

Income statement

See full
Revenue$18.5M+11.3%
Operating income-$62.9M-39.0%
Net income-$56.4M-35.7%
EPS (diluted)-$0.67+11.8%

Balance sheet

See full
Cash & equivalents$76.8M+51.5%
Total debt$26.6M-8.7%
Total equity$480.9M+185%
Total assets$615.0M+96.7%

Cash flow

See full
Operating cash flow-$61.1M-45.6%
CapEx$3.5M+20.8%
Free cash flow-$64.6M-44.0%

Valuation & ratios

Valuation

as of 02/28/25
See full
Market cap$1.17B+52.2%
Enterprise value$1.12B+49.9%
P/S20.8×+11.3×

Profitability

See full
Operating margin-408.9%-4,414pp
Net margin-369.4%-6,101pp
FCF margin-357.3%—

Returns & leverage

See full
Return on equity-64.2%-1.2pp
Debt / equity0.1×-0.1×
Current ratio6.3×+3.4×

FAQ

When did Nurix Therapeutics, Inc. report Q1 2025 earnings?
Nurix Therapeutics, Inc. (NRIX) reported Q1 2025 earnings on April 8, 2025 before market open.
What were Nurix Therapeutics, Inc.'s Q1 2025 revenue and EPS?
Nurix Therapeutics, Inc. reported revenue of $18.5M and eps of $-0.67 for Q1 2025.
Did Nurix Therapeutics, Inc. beat estimates in Q1 2025?
Revenue beat the consensus estimate of $15.8M by $2.6M. EPS beat the consensus estimate of $-0.72 by $0.05.
Where can I find Nurix Therapeutics, Inc.'s Q1 2025 SEC filings?
You can read the 8-K earnings release (0001549595-25-000053) and the 10-Q periodic report (0001549595-25-000055) directly on SEC EDGAR. The filing index links above go to sec.gov.